¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"neutral lipid storage disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® lipid ÇÑ±Û ÁöÁú
¼³¸í   
  »ý¹°Ã¼ ¾È¿¡ Á¸ÀçÇϸ砹°¿¡ ³ìÁö ¾Æ´ÏÇϰí, À¯±â¿ë¸Å¿¡ ³ì´Â À¯±âÈ­ÇÕ¹°À» ÅëÆ²¾î À̸£´Â ¸». Á¼Àº Àǹ̷δ ¹°¿¡ ³ìÁö ¾Ê°í ¾ËÄÚ¿Ã, ÄÝ·Î·ÎÆ÷¸§À̳ª ¿¡Å׸£, º¥Á¨ µîÀÇ ºñ±Ø¼º¿ë¸Å¿¡ ³ì´Â Áö¹æ»êÀÇ ¿¡½ºÅ׸£·Î »ýü¿¡ ÀÌ¿ëµÇ´Â À¯±âÈ­ÇÕ¹°ÀÌ´Ù. ´Ü¼øÁöÁú, º¹ÇÕÁöÁú(ÀÎÁöÁú, ´çÁöÁú, Áö´Ü¹é) ¹× À¯µµÁöÁú(ÁöÁúÀÇ °¡¼öºÐÇØ»ê¹°)·Î ºÐ·ùµÈ´Ù. Æ¯È÷ Áß¼ºÁö¹æÀº Áö¹æ»ê°ú ±Û¸®¼¼¸°°úÀÇ ¿¡½ºÅ׸£·Î ´Ü¹éÁú°ú ´ç°ú ÇÔ²² »ýüÀÇ Áֿ伺ºÐ ¹× ¿¡³ÊÁö¿øÀ¸·Î¼­ Áß¿äÇÏ´Ù. ±¤ÀǷδ ½ºÅ×·ÎÀ̵堵îÀ» Æ÷ÇÔÇØ¼­ È£¸£¸ó, ºñŸ¹Î ·ù·Î¼­ ÀÛ¿ëÇϴ °Í µîÀ¸·Î ´Ù¾çÇÑ »ý¸®ÇÐÀû ±â´ÉÀ» ´ã´çÇϰí ÀÖ´Ù.
¿µ¹® infectious disease ÇÑ±Û °¨¿°º´
¼³¸í   
  ¹ÙÀÌ·¯½º·ÎºÎÅÍ ±â»ýÃæ Å©±â±îÁöÀÇ »ý¹°À» ¿øÀÎÀ¸·Î Çϴ º´. ¿øÀÎÀº Á¢ÃËÀü¿°¼ºÀ̸ç, º´¿ø¿¡¼­ °¨¿°µÇ´Â °æ¿ìµµ ÀÖ´Ù. °¨¿°À» ¿øÀαտ¡ µû¶ó ºÐ·ùÇϸ頹ÙÀÌ·¯½º, ¼¼±Õ, Å¬¶ó¹Ìµð¾Æ, ¸®ÄÏÂ÷, ¹ÌÄÚ¹ÚÅ׸®¿ò, °õÆÎÀÌ, ¿øÃæ, À±Ãæ, ¿ÜºÎ±â»ýÃæ °¨¿°À¸·Î ³ª´­ ¼ö ÀÖ´Ù.
¿µ¹® hypertensive heart disease ÇÑ±Û °íÇ÷¾Ð½ÉÀ庴
¼³¸í   
  °íÇ÷¾Ð¿¡ ÀÇÇØ¼­ »ý±â´Â ½ÉÀ庴. °íÇ÷¾Ð½ÉÀ庴À̶ó´Â Áø´ÜÀ» ºÙÀ̱â À§Çؼ­´Â ÃÖ¼ÒÇÑ ´ÙÀ½°ú °°Àº Á¶°ÇÀÌ ºÎÇյǾî¾ß Çϴµ¥, Ã¹Â° ½ÉÀåÇ÷°ü°è¿¡ ½ÉÀ庴À» À¯¹ßÇÒ ¼ö ÀÖÀ» ¸¸ÇÑ ´Ù¸¥ º´º¯ÀÌ ¾øÀÌ Á½ɽǠºñ´ë°¡ ÀÖ¾î¾ß Çϸç, µÑ° °íÇ÷¾ÐÀ» ¾Î¾Ò´Ù´Â º´·ÂÀÌ ÀÖ¾î¾ß ÇÑ´Ù. ÁַΠ°íÇ÷¾Ð¿¡ ÀÇÇÑ ½ÉÀ庴Àº Ãʱ⿡´Â Á½ɽÇÀÌ ºñÈĶó´Â °ÍÀ¸·Î Æ¯Â¡µÇ¾îÁø´Ù. Áï Ç÷¾ÐÀÌ ³ôÀ¸¹Ç·Î Ç÷¾×À» ¼øÈ¯½Ã۱â À§Çؼ­´Â ±×¸¸Å­ ½ÉÀåÀÇ Ç÷¾×À» º¸³»´Â ÈûÀÌ ÁÁ¾Æ¾ß ÇÑ´Ù. ±× ÈûÀ» ¾ò±âÀ§Çؼ­´Â ½É±ÙÀÇ ºñÈİ¡ ÇÊ¿ä·Î ÇÏ¿© Á½ɽǠ±ÙÀ°ÀÇ ºñÈİ¡ »ý±ä´Ù. ±×¸®°í °íÇ÷¾ÐÀÌ Áö¼ÓÀÌ µÉ °æ¿ì¿¡´Â °á±¹ ½ÉÀåÀÌ Á¦ ±¸½ÇÀ» ÇÏÁö ¸øÇ졒ʮßÇÁ·Î¼­ÀÇ ±â´ÉÀ» ÀÒ¾î¹ö¸®°Ô µÇ¾î ½ÉÀå±â´É»ó½Ç¿¡ ºüÁö°Ô µÈ´Ù.
¿µ¹® pelvic inflammatory disease ÇÑ±Û °ñ¹Ý¿°Áúȯ
¼³¸í   
  °ñ¹ÝÁÖÀ§ÀÇ Àå±â¿¡ ¹ß»ýÇϴ ¿°ÁõÀ» ¸»ÇÔ. ÁַΠ¿©¼º¿¡¼­ ¹ß»ýÇϸ砿øÀÎÀº ÀÓ±Õ(gonococcus)°ú ºñÀÓ±Õ¿¡ ÀÇÇÑ °¨¿°(non-gonorrheal infection)¿¡ ÀÇÇÑ´Ù. Áõ»óÀº Ãʱ⿡´Â ÁúºÐºñ¹°, ÇϺ¹ºÎµ¿Åë, ¿©¼ºÀÇ »ý½Ä±âºÎÀ§¿¡ ¹ß»ýÇϴ ¾ÐÅë, ¿ù°æÅë, ¿ù°æ·®ÀÇ Áõ°¡ µîÀÌ´Ù. ÀÏÂï Ä¡·áÇØ¾ß Çϸç, °è¼ÓÀûÀ¸·Î º´ÀÌ Áö¼Ó½Ã ¿©¼ºÀÇ ºÒÀÓÀÇ ¿øÀÎÀÌ µÈ´Ù. ÈÄÁø±¹¿¡¼­´Â °¡Àå ¸¹Àº ¿©¼ººÒÀÓÀÇ ¿øÀÎÀ̱⵵ ÇÔ. Ä¡·á´Â Ç×»ýÁ¦ÀÇ Åõ¿©ÀÌ´Ù.
¿µ¹® Graves' disease ÇÑ±Û ±×·¹À̺꽺º´
¼³¸í   
  °©»ó»ùÀÇ ºñ´ë¿Í °©»ó»ùÈ£¸£¸óÀÇ °ú´ÙºÐºñ°¡ Æ¯Â¡ÀΠº´ÀÌ´Ù. ÀÌ º´Àº ÁַΠ25~50¼¼¿¡ È£¹ßÇϰí ÁַΠ¿©ÀÚ¿¡°Ô¼­ ¸¹ÀÌ »ý±ä´Ù. °©»ó»ù È£¸£¸óÀº ÀúÀåµÇ¾î Àִ ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ¿© ½ÅüÀÇ ´ë»çÀ²À» ³ôÀ̴ ȣ¸£¸óÀ̹ǷΠÀÔ¸ÀÀÌ ÁÁÀº µ¥µµ ºÒ±¸Ç졒ʡè¼ÓÀûÀΠüÁßÀÇ °¨¼Ò, ±×¸®°í ÃàÀûµÈ ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ¿© ¿­»ý¸¹ÀÌ ÇÏ¿©¼­ ´õÀ§¸¦ Âü±â Èûµé¾îÇÏ°í ¸¸¼º ¼è¾à°¨À̳ª ±Ù·ÂÀÇ ¾àÈ­¸¦ º¸ÀÏ ¼ö°¡ ÀÖ´Ù. ±×¸®°í ´«¿¡ Æ¯Â¡ÀûÀΠÁõ»óÀÌ ³ªÅ¸³ª´Âµ¥ ´«²¨Ç®ÀÌ ºñÁ¤»óÀûÀ¸·Î À§·Î ¿Ã¶ó°¡ ÀÖ°í, ´«ÀÌ ¾Æ·¡ÀÇ ¹°°ÇÀ» ÁÖ½ÃÇÒ °æ¿ì¿¡ ´«²¨Ç®ÀÌ Á¤»óÀûÀ¸·Î´Â Ã³Á®¾ß ÇÏÁö¸¸ °©»ó»ù È£¸£¸óÀÌ °úµµÇϰԠ³ª¿Ã °æ¿ì¿¡´Â ´«²¨Ç®À̠óÁöÁö ¾Ê´Â´Ù. ¶Ç ´«¾ËÀÌ ¾ÕÂÊÀ¸·Î µ¹ÃâÇϴ ¾È±¸µ¹ÃâÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¶Ç ÇǺΰ¡ ¾ÆÁÖ ºÎµå·´°í ¹°±â°¡ ¸¹¾Æ¼­ ÃàÃàÇÏ´Ù. ±×¸®°í Æ¯Â¡ÀûÀ¸·Î ÇÏÁöÀÇ ¾ÕÂÊ¿¡ ÇǺΰ¡ µÎ²¨¿öÁ® ±¹¼ÒÀû À¶±â¸¦ ÀÌ·ç´Â °ÍÀÌ Àִµ¥ À̰ÍÀº ÀÌ º´ÀǠƯ¡ÀûÀΠº´ÅÍÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • copper storage disease
    ±¸¸®ÃàÀûº´
  • cystine storage disease
    ½Ã½ºÆ¾ÃàÀûº´
  • cholesteryl ester storage disease
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅ׸£ÃàÀûº´
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûº´, ´ç¿øÃàÀûº´
  • iron-storage disease
    öÃàÀûÁúȯ
  • lysosomal storage disease
    ¿ëÇØ¼ÒüÃàÀûº´, ¸®¼ÒÁ»ÃàÀûº´
  • phytanic acid storage disease
    ÇÇź»êÃàÀûº´
  • storage disease
    ÃàÀûº´
  • neutral fat
    Áß¼ºÁö¹æ
  • neutral occlusion
    Á¤»ó¸Â¹°¸², Á¤»ó±³ÇÕ
  • neutral reaction
    Áß¼º¹ÝÀÀ, ÁßÈ­¹ÝÀÀ
  • neutral salt
    Áß¼º¿°
  • neutral stain
    Áß¼º¿°»ö
  • neutral zone
    Ç׿øÇ×üÆòÇü±¸¿ª
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • storage disease
    ÃàÀûº´
  • lipid
    ÁöÁú
  • storage iron
    ˜ˌ̦
  • storage-type
    ÃàÀûÇü
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • anemia of chronic disease
    ¸¸¼ºº´ºóÇ÷
  • disease
    º´, Áúȯ, Áúº´
  • adult disease
    (¢¡life style disease) »ýȰ½À°üº´
  • Alzheimer disease
    ¾ËÃ÷ÇÏÀ̸Ӻ´
  • Behcet's disease
    º£Ã¼Æ®º´
  • Buerger's disease
    (¢¡ thromboangiitis obliterans) Æó¼âÇ÷ÀüÇ÷°ü¿°
  • cerebrovascular disease
    ³úÇ÷°üº´, ³úÇ÷°üÁúȯ
  • congenital heart disease
    ¼±Ãµ½ÉÀ庴
  • Crohn's disease
    Å©·Ðº´
  • Cushing's disease
    Äí½Ìº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • copper storage disease
    ±¸¸®ÀúÀ庴
  • cystine storage disease
    ½Ã½ºÆ¾ÃàÀûº´
  • glucose storage disease
    ´çÃàÀûº´
  • glycogen storage disease
    ´ç¿øÃàÀûº´
  • lysosomal storage disease
    ¸®¼Ò¼ØÃàÀûº´, ¿ëÇØ¼ÒüÃàÀûº´
  • neuronal storage disease
    ½Å°æ¼¼Æ÷ÀúÀ庴
  • storage disease
    ÃàÀûº´
  • neutral fat
    Áß¼ºÁö¹æ
  • neutral hermaphroditism
    Áß¼º³²³àÇѸöÁõ
  • neutral occlusion
    Á¤»ó¸Â¹°¸², Á¤»ó±³ÇÕ
  • neutral reaction
    ÁßÈ­¹ÝÀÀ
  • neutral salt
    Áß¼º¿°
  • neutral zone
    Ç׿øÇ×üÆòÇü±¸¿ª
  • lipid granule
    Áö¹æ°ú¸³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Dorfman-Chanarin syndrome = neutral lipid storage disease
    Áß¼ºÁö¹æÃàÀûÁõ
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • Lipid Research Clinic
    ÁöÁú¿¬±¸Áø·á¼Ò
  • Lipid bilayer
    Áö¹æÀÌÁßÃþ(ò·Û¸ì£ñìöµ)
  • free radical formation,lipid peroxidation
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, ÁöÁú °ú»êÈ­(ò·òõ Φ߫ûù)
  • granule, lipid
    Áö¹æ°ú¸³
  • image storage
    ¿µ»óÀúÀå<--ÃàÀû
  • ABO hemolytic disease
    ABO ¿ëÇ÷¼º Áúȯ(¡­éÁúìàõ òðü´)
  • ABO hemolytic disease of the newborn
    ½Å»ý¾Æ ABO ¿ëÇ÷¼ºÁúȯ
  • Addisons disease
    ¾Æµð¼Õ º´
  • Addisons disease
    ¾Öµð½¼º´ ºÎ½Å±â´ÉºÎÀü .
  • Aleutian mink disease virus
    ¾Ë·ù»ê¹ÖÅ©º´ ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid storage disease
    ÁöÁúÃàÀûÁõ
  • lipid storage disease
    ÁöÁúÃàÀûÁõ.
  • ceroid storage disease
    ¼¼·ÎÀ̵åÃàÀûÁúȯ.
  • copper storage disease
    µ¿ÀúÀåÁúȯ(ÔÞîÍíúòðü´).
  • cystine storage disease
    ½Ã½ºÆ¾(ÃàÀû)º´ (¡­õëîÝÜ»).
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • lysosomal storage disease
    ¸®¼Ò¼Ø ÃàÀûÁõ
  • neuronal storage disease
    ½Å°æ¼¼Æ÷¼ºÀúÀåÁúȯ(¡­á¬øààõîÍíúòðü´)
  • storage disease
    ÃàÀûÁõ(õåîÝñø)
  • storage pool disease
    ÀúÀåÇ®º´(ÀúÀåǮܻ)
  • type II glycogen storage disease
    ´ç¿øÀúÀ庴IIÇü(ÓØê«îÍíúÜ»ì£úþ).
  • neutral
    Áß¼º(ñéàõ)ÀÇ, ÁßÈ­(ñéûú)ÀÇ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Lipid drop
    Áö¹æ¹æ¿ï
    [¿¾ ¿ë¾î] Áö¹æ¼ÒÀû
  • Lipid droplet
    Áö¹æ¹æ¿ï
    [¿¾ ¿ë¾î] Áö¹æ¼ÒÀû
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arthropod-borne disease
    ÀýÁöµ¿¹°¸Å°³Áúº´
  • Chagas' disease
    »þ°¡½ºº´
  • endemic disease
    dzÅ亴
  • enzootic disease
    µ¿¹°ÅäÂøº´
  • helminthic disease
    ¿¬ÃæÁúȯ
  • hookworm disease
    ±¸Ã溴
  • hydatid disease
    Æ÷Ãæº´
  • insect borne disease
    °ïÃæ¸Å°³Áúȯ
  • metazoal disease
    ÈÄ»ýµ¿¹°Áúȯ
  • parasitic disease
    ±â»ýÃæº´
  • protozoan disease
    ¿øÃæÁúȯ, ¿øÃ溴
  • tropical disease
    ¿­´ëº´, ¿­´ëÁúȯ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid storage disease
    ÁöÁúÀúÀåÁúȯ(ò·òõîÍíúòðü´)
  • glycogen storage disease
    ±Û¶óÀÌÄÚÀü ÀúÀå Áúȯ(îÍíúòðü´)
  • lysosomal storage disease
    ¶óÀ̼ÒÁ»³»(Ò®) ÀúÀåÁúȯ(îÍíúòðü´)
  • mucopolysaccharide storage disease
    ¹ÂÄÚ´Ù´çÁú(ÒýÓØòõ)ÀúÀåÁúȯ(îÍíúòðü´)
  • neutral lipid
    Áß¼ºÁöÁú(ñéàõò·òõ)
  • phytanic acid storage syndrome
    ÇÇź»ê(ß«) ÃàÀû ÁõÈıº(õëîÝñøý¦ÏØ)
  • storage mRNA
    ÀúÀå(îÍíú) mRNA
  • calcium-activated neutral proteinase
    Ä®½·ºÎȰ(Ý·üÀ) Áß¼º(ñéàõ)ÇÁ·ÎƼ³×À̽º
  • coupled neutral pump
    °ø¿ª(Íëæµ) ÁßÈ­(ñéûú) ÆßÇÁ
  • neutral amino acid
    Áß¼º(ñéàõ) ¾Æ¹Ì³ë»ê(ß«)
  • neutral fat
    Áß¼ºÁö¹æ(ñéàõò·Û¸)
  • neutral glycolipids
    Áß¼º´çÁöÁú(ñéàõÓØò·òõ)
  • neutral mutation
    Á߸³º¯ÀÌ(ñ騡܍ì¶)
  • neutral sugar
    Áß¼º ´ç(ñéàõÓØ)
  • neutral theory of molecular evolution
    Á߸³ºÐÀÚÁøÈ­·Ð(ñ騡ÝÂí­òäûùÖå)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neutral
    Áß¼ºÀÇ, ÁßÈ­ÀÇ
  • glycogen storage disease
    ±Û¸®ÄÚ°Õ ÃàÀûÁúȯ
  • storage disease
    ÃàÀûÁõ
  • lipid bound proton
    Áö¹æ°áÇվ缺ÀÚ
  • lipid-laden
    Áö¹æÀûÀç
  • long-term storage
    Àå±âÀúÀå(ÀåÄ¡)
  • short-term storage
    ´Ü±âÀúÀå(ÀåÄ¡)
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • storage oscilloscope
    ÀúÀå½Ä¿À½Ç·Î½ºÄÚÇÁ
  • storage tube
    ÀúÀå°ü
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
  • acquired heart disease
    ÈÄõ¼º½ÉÀåÁúȯ
  • Addison's disease
    ¾Öµð½¼º´
  • air space disease
    °ø°£Áúȯ
  • caisson disease
    ÀáÇÔº´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
INLSD ichthyosis and neutral lipid storage disease
ND Doctor of Naturopathy; nasal deformity; natural death; Naval Dispensary; neonatal death; neoplastic ...
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
MD Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NL Neutral lipid
CESD Cholesterol ester storage disease
GSD Glycogen Storage Disease
GSDII Glycogen Storage Disease type II
GSD 1a Glycogen storage disease type 1a
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lipid storage
    Áö¹æ ÀúÀå
    Áö¹æ ¼¼Æ÷°¡ ´ã´çÇÏ´Â ±â´ÉÀ¸·Î ü³»¿¡ Èí¼öµÈ Áö¹æÀº ų·Î¹ÌÅ©·ÐÀÇ ÇüÅ·Πü¼øÈ¯À» ÇÏ°Ô µÇ¸ç, Áö¹æ Á¶Á÷ÀÇ ¸ð¼¼Ç÷°ü¿¡ À̸£¸é ³»ÇÇ ¼¼Æ÷ÀÇ ´çÁöÁú ¸®ÆÄ¾ÆÁ¦ÀÇ ÀÛ¿ëÀ¸·Î À¯¸® Áö¹æ»ê°ú ´Ü´ç·ù·Î ºÐÇØµÇ¾î Áö¹æ ¼¼Æ÷¿¡ ÀÇÇØ ´Ü¼ø È®»êÀ¸·Î ¼·ÃëµÈ´Ù. ÀÌ Áö¹æ»êÀº Áö¹æ ÇÕ¼º È¿¼Ò¿¡ ÀÇÇÏ¿© Áß¼º Áö¹æÀ¸·Î ÇÕ¼ºµÇ¸ç Áö¹æ ºÐÇØ È¿¼Ò¸¦ ¾ïÁ¦ÇÏ¿© Áö¹æÀ» ÃàÀû½ÃŲ´Ù.
  • neuronal storage disease
    ½Å°æ ÃàÀûÁõ
  • storage pool disease
    ÀúÀåÁ¶º´
    ÀÀÁýÁ¦, ¿¡Çdz×ÇÁ¸°, ¿ÜÀμº ADP, Æ®·Òºó µî¿¡ ¹ÝÀÀÇÏ¿© ADP¸¦ ¹æÃâÇÏ´Â Ç÷¼ÒÆÇ ±â´É ºÎÀü¿¡ ÀÇÇÑ Ç÷¾× ÀÀ°í Àå¾Ö, °¡º­¿î ÃâÇ÷ Áõ»ó, ÃâÇ÷ ½Ã°£ Áö¿¬, ±³¿øÁúÀ̳ª Æ®·Òºó¿¡ ´ëÇÑ ÀÀÁý ¹ÝÀÀÀÇ °¨Å𸦠Ư¡À¸·Î ÇÑ´Ù.
  • lipid bilayer
    Áö¹æÁú Ãþ
    ¼¼Æ÷¸·Àº ÁöÁú ÀÌÁß ÃþÀ̶ó Çϸç, ÀÌ Áö¹æÁú ÃþÀº ÁÖ·Î ÀÎ ÁöÁú¿¡ ÀÇÇØ ±¸¼ºµÇ¾î ÀÖ´Ù. ÀÎ ÁöÁúÀº Ä£¼ö¼º°ú ¼Ò¼ö¼º ºÎÀ§·Î ±¸¼ºµÇ¾î ¼¼Æ÷¸·ÀÇ ¹°Áú À̵¿¿¡ ¿µÇâÀ» ³¢Ä£´Ù. ¶Ç Áö¹æÁú ÃþÀÇ ÄÝ·¹½ºÅ×·ÑÀº ÀÌ ÃþÀÇ ¾ÈÁ¤È­¸¦ µ½´Â´Ù.
  • lipid metabolism
    ÁöÁú ´ë»ç
    °£¿¡¼­ ÈçÈ÷ ÀϾ¸ç Áö¹æ»êÀÇ º£Å¸-»êÈ­ ¹× ¾Æ¼¼Æ® ¾Æ¼¼Å×ÀÌÆ® Çü¼º, ´ç ÁöÁú »ý¼º, ÄÝ·¹½ºÅ×·Ñ ¹× ÀÎ ÁöÁú Çü¼º, ´ç°ú ´Ü¹éÁú·ÎºÎÅÍ Áö¹æÀÇ Àüȯ µîÀÌ °¡Àå ´ëÇ¥ÀûÀÌ´Ù.
  • lipid proteinosis
    ÁöÁú ´Ü¹éÁõ
  • lipid-filled histocyte
    ÁöÁú·Î ä¿öÁø Á¶Á÷±¸
  • neutral
    Áß¼ºÀÇ, Á߸³ÀÇ, ÁßÈ­ÀÇ
    È­ÇÐÀûÀ¸·Î »ê¼ºµµ ¾Æ´Ï°í ¿°±â¼ºµµ ¾Æ´Ñ.
  • neutral formaldehyde
    Áß¼º Æ÷¸§ ¾Ëµ¥ÇÏÀ̵å
  • neutral occlusion
    Á¤»ó ±³ÇÕ
    µ¿ÀǾî=normal occlusion.
  • neutral space
    Á߸³°­, Á߸³ °ø°£
  • serum neutral fat
    Ç÷û Áß¼º Áö¹æ
    Ç÷û Áß¼º Áö¹æÀº ´ëºÎºÐÀÌ Æ®¸®±Û¸®¼¼¶óÀ̵åÀ̰í, ±× ³óµµ´Â À½½Ä¹°ÀÇ ¿µÇâÀ» ¹Þ´Â´Ù.
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
    Ä¡°ú º¸Ã¶ ¿µ¿ª¿¡¼­´Â °¡Ã¶ ÀÇÄ¡ÀÇ ºÐ½Ç, ÆÄ¼Õ, ¹× º¯ÇüÀ» ¿¹¹æÇϱâ À§ÇÏ¿© ¾ÈÀüÇÑ Àå¼ÒÀÎ ¹° ¼Ó¿¡ µÎ´Â °Í.
  • storage of drug
    ¾à¹°ÀÇ º¸°ü
  • kufs's disease °¡Á·¼º Èæ³»À强 ¹éÄ¡ÀÇ ¸¸¹ß¼º ¿¬¼ÒÇüÀÌ´Ù.

    Kugelberg-Welander disease ±Ù À§ÃàÁõÀÇ À¯Àü¼º ¿¬¼ÒÇüÀ¸·Î¼­ º¸Åë »ó¿°»öü¼º ¿­¼º ÇüÁú·Î À¯ÀüµÈ´Ù. ô¼ö Àü°¢ÀÇ º´º¯ÀÌ ±× ¿øÀÎÀÌ´Ù.

    kukuruku ¿øÀÎ ºÒ¸íÀ̸ç, ³ªÀÌÁö¸®¾Æ¿¡¼­ º¼ ¼ö ÀÖ´Â ÁúȯÀ¸·Î, ¿­

    °£Àå ´ë½Ä ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
neutral lipid storage disease <syndrome> Congenital ichthyosis, leukocyte vacuoles, and variable involvement of other organ systems.
Synonym: neutral lipid storage disease.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
disease, lipid storage A series of disorders due to inborn errors in lipid metabolism resulting in the abnormal accumulation of lipids in the wrong places (Examples include Gaucher, Fabry and Niemann-Pick diseases and metachromatic leukodystrophy).
(12 Dec 1998)
lipid storage diseases A series of disorders due to inborn errors in lipid metabolism resulting in the abnormal accumulation of lipids in the wrong places (examples include gaucher, fabry and niemann-pick diseases and metachromatic leukodystrophy).
(12 Dec 1998)
brancher glycogen storage disease Type of glycogen storage disease, due to deficiency of amylo-1,4-1,6-transglucosidase (brancher enzyme).
Synonym: brancher deficiency glycogenosis, debrancher deficiency.
(05 Mar 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
cholesterol ester storage disease A rare benign adult form of inherited lysosomal lipid storage disease that is due to deficiency of acid lipase. It results in an accumulation of neutral lipids, particularly cholesterol esters, within cells (particularly leukocytes, fibroblasts, and liver cells). It is an allelic variant of wolman disease.
(12 Dec 1998)
phytanic acid storage disease A genetic disorder of the fatty acid phytanic acid which accumulates and causes a number of progressive problems including polyneuritis (inflammation of numerous nerves), diminishing vision (due to retinitis pigmentosa), and wobbliness (ataxia) caused by damage to the cerebellar portion of the brain (cerebellar ataxia).
(12 Dec 1998)
cystine storage disease Lysosomal storage disorders of unknown molecular defect, characterised by widespread deposition of cystine crystals in reticuloendothelial cells.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipid
    ÁöÁú
  • neutral
    Á߸³ÀÇ
  • Idiom Neutral
    À̵ð¾ö ´ºÆ®·²(1902³â¿¡ ¹ßÇ¥µÈ ÀΰøÀû ±¹Á¦ º¸Á¶¾î)
  • neutral
    Á߸³(±¹)ÀÇ;Á߸³±¹;ºÒÆíºÎ´çÀÇ;¾î´ÀÆíµµ µéÁö ¾Ê´Â;(Á¾·ù,Ư¡)ºÐ¸íÄ¡ ¾ÊÀº;(»öÀÌ)¹Ù·£;ȸ»öÀÇ;Áß¼ºÀÇ;¾Ï¼ö ±¸º°ÀÌ ¾ø´Â;(ÇôÀÇ À§Ä¡°¡)Áß¼ºÀÇ;Áß°£ÀÇ;Á߸®±¹(¹Î);Á߸³ÀÚ;(Àüµ¿±â¾îÀÇ)Á߸³(À§Ä¡)
  • neutral corner
    ´ºÆ®·² ÄÚ³Ê(°æ±âÀÚÀÇ ÈÞ°Ô¿ëÀ¸·Î ÁöÁ¤µÇ¾î ÀÖÁö ¾ÊÀº ÄÚ³Ê)
  • neutral current
    Á߸³Àû ¼Ò¸³ÀÚ·ù;Áß¼º Ä¿·»Æ®
  • neutral meson
    Áß¼º Áß°£ÀÚ(neutretto)
  • neutral mutation
    Á߸³µ¹¿¬º¯ÀÌ
  • neutral spirits
    Áß¼º ÁÖÁ¤(95µµ ÀÌ»ó¼ø¼ö ¾ËÄÚ¿Ã,º¸Åë ´Ù¸¥ ¼ú°ú ¼¯¾î¸¶½É)
  • neutral tint
    Áß°£»ö;¿¬ÇÑȸ»ö
  • neutral zone
    Áß°£Áö´ë
  • storage
    ÀúÀå,º¸°ü,â°í,ÃàÀü
  • cold storage
    (¸ÔÀ» °ÍµîÀÇ)ÀïÀå;µ¿°á»óÅÂ;¹¦;¹¦Áö
  • control storage
    Á¦¾î±â¾ïÀåÄ¡
  • core storage
    ÀÚ½É ±â¾ï ÀåÄ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á